Cardiovascular Diseases
Conditions
Brief summary
Cardiovascular (CV) events are the leading cause of mortality in the United States. Statins have been demonstrated to be an effective tool for reducing CV events and mortality, but statins are often either not prescribed or under-prescribed for patients that meet evidence-based guidelines. In this study, we will evaluate a health system initiative using active and passive choice prompts in the electronic health record to prompt cardiologists to prescribe evidence-based statin therapy. In partnership with the health system, this will be conducted as a randomized, controlled trial to evaluate its effect.
Detailed description
This study will use a randomized, controlled trial to evaluate a health system initiative. Cardiologists randomly assigned to the control arm will receive no interventions. For cardiologists randomly assigned to the active choice intervention, the electronic health record will be used to prompt cardiologists to initiate or change statin therapy for patients not on evidenced-based guidelines based on the 2013 American College of Cardiology / American Heart Association (ACC/AHA) and the National Lipid Association (NLA) through a best practice alert in Epic which appears on the screen and forces a decision before the clinician can move on. For cardiologists randomly assigned to the passive choice intervention, the electronic health record will be used to create a passive alert using the same evidence-based guidelines. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision. The intervention period will be 6 months in duration.
Interventions
EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
EHR passive alert to cardiologists about prescribing a statin
Sponsors
Study design
Eligibility
Inclusion criteria
* Have a cardiologist at the University of Pennsylvania Health System * Meets 2013 ACC/AHA or NLA guidelines for statin prescription
Exclusion criteria
* Allergy to statins * Severe renal insufficiency defined as glomerular filtration rate (GFR) less than 30 mL/min or on dialysis * Adverse reaction to statins including a) myopathy, b)rhabdomyolysis, c)hepatitis * Pregnant * On a PCSK9 Inhibitor medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the percent of eligible patients prescribed statin therapy at a dose that meets evidence-based guidelines | 6 Months | Among patients not on guideline-based statin dosages, the percent that are prescribed guideline-based therapy at appropriate dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in percentage of eligible patients prescribed a statin, at any dose. | 6 Months | Among patients not on a statin, the percent that are prescribed guideline-based therapy, at any dose. |
Countries
United States